Pacira BioSciences, Inc. financial data

Symbol
PCRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
5401 West Kennedy Boulevard, Suite 890, Tampa, Florida
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Pacira Pharmaceuticals, Inc. (to 4/9/2019), PACIRA INC (to 11/5/2008), Blue Acquisition Corp (to 4/16/2007)
Latest financial report
10-Q - Q2 2024 - Jul 30, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 565 % +49.9%
Quick Ratio 106 % +37%
Debt-to-equity 82.5 % -23.4%
Return On Equity 7.32 %
Return On Assets 4.01 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 46.1M shares -0.63%
Common Stock, Shares, Outstanding 46.1M shares -0.63%
Common Stock, Value, Issued 47K USD +2.17%
Weighted Average Number of Shares Outstanding, Basic 46.2M shares +0.19%
Weighted Average Number of Shares Outstanding, Diluted 50.5M shares -2.91%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 690M USD +3.15%
Cost of Revenue 179M USD -14.6%
Research and Development Expense 78.9M USD +8.23%
Costs and Expenses 598M USD -3.72%
Operating Income (Loss) 92.3M USD +91.7%
Nonoperating Income (Expense) 8.2M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 101M USD -3.36%
Income Tax Expense (Benefit) 37M USD +46.4%
Net Income (Loss) Attributable to Parent 63.6M USD -26.7%
Earnings Per Share, Basic 1.38 USD/shares -26.8%
Earnings Per Share, Diluted 1.39 USD/shares -23.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 247M USD +185%
Accounts Receivable, after Allowance for Credit Loss, Current 105M USD +5.75%
Inventory, Net 103M USD +12.3%
Assets, Current 632M USD +47.3%
Deferred Income Tax Assets, Net 135M USD -13.5%
Property, Plant and Equipment, Net 169M USD -6.36%
Operating Lease, Right-of-Use Asset 56.3M USD -14.5%
Intangible Assets, Net (Excluding Goodwill) 455M USD -11.2%
Goodwill 163M USD 0%
Assets 1.65B USD +6.77%
Accounts Payable, Current 18.7M USD -22.6%
Accrued Liabilities, Current 64.8M USD +15.3%
Liabilities, Current 92.7M USD -14.9%
Operating Lease, Liability, Noncurrent 50.1M USD -16.5%
Other Liabilities, Noncurrent 13M USD +10.4%
Liabilities 768M USD +4.51%
Accumulated Other Comprehensive Income (Loss), Net of Tax 105K USD
Retained Earnings (Accumulated Deficit) -78.9M USD +44.6%
Stockholders' Equity Attributable to Parent 879M USD +8.83%
Liabilities and Equity 1.65B USD +6.77%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 47M shares +1.18%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 247M USD +185%
Operating Lease, Liability 59.3M USD -14.1%
Depreciation 16.9M USD -47.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 63.9M USD -26.8%
Lessee, Operating Lease, Liability, to be Paid 72.1M USD -16.9%
Property, Plant and Equipment, Gross 293M USD -5%
Operating Lease, Liability, Current 9.15M USD +1.87%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.8M USD -1.95%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.8M USD -8.19%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12.8M USD -27.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.6M USD -1.77%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10.9M USD -13.2%
Additional Paid in Capital 983M USD +3.42%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 57.3M USD 0%
Share-based Payment Arrangement, Expense 50.6M USD +4.81%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%